200 related articles for article (PubMed ID: 19485295)
1. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections.
Kahook MY; Kimura AE; Wong LJ; Ammar DA; Maycotte MA; Mandava N
Ophthalmic Surg Lasers Imaging; 2009; 40(3):293-5. PubMed ID: 19485295
[TBL] [Abstract][Full Text] [Related]
2. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
3. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.
Mathalone N; Arodi-Golan A; Sar S; Wolfson Y; Shalem M; Lavi I; Geyer O
Graefes Arch Clin Exp Ophthalmol; 2012 Oct; 250(10):1435-40. PubMed ID: 22434210
[TBL] [Abstract][Full Text] [Related]
4. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
[TBL] [Abstract][Full Text] [Related]
5. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
[TBL] [Abstract][Full Text] [Related]
6. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Tseng JJ; Vance SK; Della Torre KE; Mendonca LS; Cooney MJ; Klancnik JM; Sorenson JA; Freund KB
J Glaucoma; 2012; 21(4):241-7. PubMed ID: 21423038
[TBL] [Abstract][Full Text] [Related]
7. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
Adelman RA; Zheng Q; Mayer HR
J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
[TBL] [Abstract][Full Text] [Related]
8. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections.
Skalicky SE; Ho I; Agar A; Bank A
Ophthalmic Surg Lasers Imaging; 2012 Jul; 43(4):328-34. PubMed ID: 22788585
[TBL] [Abstract][Full Text] [Related]
9. Persisent ocular hypertension following intravitreal ranibizumab.
Bakri SJ; McCannel CA; Edwards AO; Moshfeghi DM
Graefes Arch Clin Exp Ophthalmol; 2008 Jul; 246(7):955-8. PubMed ID: 18425523
[TBL] [Abstract][Full Text] [Related]
10. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
11. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
Good TJ; Kimura AE; Mandava N; Kahook MY
Br J Ophthalmol; 2011 Aug; 95(8):1111-4. PubMed ID: 20702430
[TBL] [Abstract][Full Text] [Related]
12. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M;
JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991
[TBL] [Abstract][Full Text] [Related]
13. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
14. Short-term intraocular pressure changes after intravitreal injection of bevacizumab.
Hollands H; Wong J; Bruen R; Campbell RJ; Sharma S; Gale J
Can J Ophthalmol; 2007 Dec; 42(6):807-11. PubMed ID: 18026202
[TBL] [Abstract][Full Text] [Related]
15. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
Ronan SM; Yoganathan P; Chien FY; Corcóstegui IA; Blumenkranz MS; Deramo VA; Elner SG; Fastenberg DA; Johnson MW; López M; Mateo C; Moshfeghi DM; Navarro R; Rosenblatt BJ; Sanislo SR; Saxe SJ; Zacks DN
Retina; 2007 Jun; 27(5):535-40. PubMed ID: 17558313
[TBL] [Abstract][Full Text] [Related]
16. Paracentesis before intravitreal injection of bevacizumab.
Tsui YP; Chiang CC; Tsai YY
Can J Ophthalmol; 2008 Apr; 43(2):239; author reply 239-40. PubMed ID: 18347632
[No Abstract] [Full Text] [Related]
17. Does intravitreal injections of bevacizumab for age-related macular degeneration affect long-term intraocular pressure?
Kim D; Nam WH; Kim HK; Yi K
J Glaucoma; 2014 Sep; 23(7):446-8. PubMed ID: 23632401
[TBL] [Abstract][Full Text] [Related]
18. Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma.
Agard E; Elchehab H; Ract-Madoux G; Russo A; Lagenaite C; Dot C
Can J Ophthalmol; 2015 Apr; 50(2):127-31. PubMed ID: 25863852
[TBL] [Abstract][Full Text] [Related]
19. Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy.
Aref AA
Curr Opin Ophthalmol; 2012 Mar; 23(2):105-10. PubMed ID: 22249237
[TBL] [Abstract][Full Text] [Related]
20. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
